Skip to main content
Premium Trial:

Request an Annual Quote

Epic Sciences Receives CAP Accreditation

NEW YORK (GenomeWeb) – Epic Sciences announced today that its San Diego laboratory has received accreditation from the College of American Pathologists.

Epic markets a platform it calls "no cell left behind," which isolates circulating tumor cells in an unbiased manner, allowing downstream analyses of single CTCs using genomic, proteomic, and morphologic approaches.

CAP accreditation is designed to ensure a high standard of care for the laboratory testing of patient samples. As part of the process, CAP inspectors examine a lab's records and quality control of procedures, as well staff qualifications, equipment, facilities, safety records, and overall management.

Epic Sciences said it has analyzed more than 10,000 blood samples from cancer patients and that its technology is being used in more than 58 active clinical trials.

The company received CLIA certification for its lab in early 2015.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.